Bevacizumab biosimilar (Allergan/Amgen)

N/A

Report date: 2022/01/17 12:14:22

Base Information

Drug NameBevacizumab biosimilar (Allergan/Amgen)
Drug Alias NameBevacizumab-awwb贝伐单抗生物仿制药（Allergan/Amgen）贝伐人源化单抗生物类似药（Allergan/Amgen）贝伐人源化单抗生物仿制药（Allergan/Amgen）贝伐单抗生物类似药（Allergan/Amgen） +[9] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/09/14
Country/TerritoryBulgariaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Technology (Ireland) Unlimited CompanyAmgen IncDaiichi Sankyo Co Ltd
Inactive CompaniesAmgen Biotechnology Consultation (Shanghai) Co Ltd
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A